CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1.39M, lower than 95% of all stocks globally
- PositionOperating margin is -10396.2%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
736.13MUSDvs all stocks (USD)
Revenue (TTM)
1.39MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.2020xvs all stocks
52-Week Change
-30.34%vs all stocks
Market Capitalization
736.13MUSDvs all stocks (USD)
Enterprise Value
638.67MUSDvs all stocks (USD)
Forward P/E
-6.00xvs Biotechnology peers
Price to Book (MRQ)
3.03xvs Biotechnology peers
Enterprise to Revenue
459.79xvs Biotechnology peers
Enterprise to EBITDA
-6.20xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-23.27%vs Biotechnology peers
Return on Equity (TTM)
-52.66%vs Biotechnology peers
Revenue (TTM)
1.39MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0200USDUpdated Jul 19, 2026Quarterly Revenue Growth
-26.70%vs Biotechnology peers
Gross Profit (TTM)
-68.32MUSDvs all stocks (USD)
EBITDA (TTM)
-102.96MUSDvs all stocks (USD)
Net Income (TTM)
-117.01MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-77.53MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-34.34MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00CHFFY2025 · Dec 31, 2025Operating Income
-81.67MCHF-100.77M · vs all stocks (USD)
Pre-tax Income
-99.14MCHFFY2025 · Dec 31, 2025Income Tax Expense
-186.00KCHFFY2025 · Dec 31, 2025Net Income
-98.96MCHFFY2025 · Dec 31, 2025EBIT
-98.31MCHFFY2025 · Dec 31, 2025EBITDA (Income Statement)
-79.36MCHFFY2025 · Dec 31, 2025Research & Development
57.09MCHFFY2025 · Dec 31, 2025Selling, General & Administrative
23.20MCHFFY2025 · Dec 31, 2025Other Operating Expenses
1.19MCHFFY2025 · Dec 31, 2025Non-operating Interest Income
1.77MCHFFY2025 · Dec 31, 2025Non-operating Interest Expense
833.00KCHFFY2025 · Dec 31, 2025EPS (Basic)
-1.89CHFFY2025 · Dec 31, 2025EPS (Diluted)
-1.89CHFFY2025 · Dec 31, 2025Basic Shares Outstanding
52.36MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
52.36MSharesFY2025 · Dec 31, 2025Operating Cash Flow
-78.64MCHFFY2025 · Dec 31, 2025Free Cash Flow
-78.94MCHFFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
81.33MCHFFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-99.14MCHFFY2025 · Dec 31, 2025Depreciation & Amortization
546.00KCHFFY2025 · Dec 31, 2025Stock-based Compensation
16.04MCHFFY2025 · Dec 31, 2025Other Non-cash Items
3.98MCHFFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-364.00KCHFFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.95MCHFFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.24MCHFFY2025 · Dec 31, 2025Capital Expenditures
-301.00KCHFFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.09MCHFFY2025 · Dec 31, 2025Purchase of Investments
-60.79MCHFFY2025 · Dec 31, 2025Net Investing Cash Flow
-61.09MCHFFY2025 · Dec 31, 2025Long-term Debt Payments
-373.00KCHFFY2025 · Dec 31, 2025Common Dividends Paid
0.00CHFFY2025 · Dec 31, 2025Other Financing Charges
-13.22MCHFFY2025 · Dec 31, 2025Net Financing Cash Flow
165.26MCHFFY2025 · Dec 31, 2025Shares Outstanding
60.39MSharesUpdated Jul 19, 2026Float Shares
52.12MSharesUpdated Jul 19, 2026Shares Short
1.18MSharesUpdated Jul 19, 2026Short Ratio
1.01daysvs all stocks
Short % of Shares Outstanding
2.26%vs all stocks
% Held by Insiders
3.51%vs all stocks
% Held by Institutions
38.98%vs all stocks
Total Cash (MRQ)
274.63MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.68USDUpdated Jul 19, 2026Total Debt (MRQ)
2.78MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0114xvs Biotechnology peers
Current Ratio (MRQ)
5.18xvs Biotechnology peers
Book Value per Share (MRQ)
4.03USDUpdated Jul 19, 2026Total Assets
235.96MCHF291.14M · vs all stocks (USD)
Total Current Assets
218.89MCHFFY2025 · Dec 31, 2025Total Liabilities
39.89MCHFFY2025 · Dec 31, 2025Total Non-current Assets
17.07MCHFFY2025 · Dec 31, 2025Total Non-current Liabilities
3.15MCHFFY2025 · Dec 31, 2025Total Current Liabilities
36.75MCHFFY2025 · Dec 31, 2025Cash & Cash Equivalents
81.33MCHFFY2025 · Dec 31, 2025Other Short-term Investments
131.68MCHFFY2025 · Dec 31, 2025Accounts Payable
1.80MCHFFY2025 · Dec 31, 2025Short-term Debt
502.00KCHFFY2025 · Dec 31, 2025Other Current Liabilities
14.48MCHFFY2025 · Dec 31, 2025Long-term Debt
1.81MCHFFY2025 · Dec 31, 2025Common Stock (Book)
587.00KCHFFY2025 · Dec 31, 2025Retained Earnings
-384.51MCHFFY2025 · Dec 31, 2025Total Shareholders' Equity
196.07MCHF241.92M · vs all stocks (USD)
Treasury Stock
7.00KCHFFY2025 · Dec 31, 202552-Week Low
10.52USDUpdated Jul 19, 202652-Week High
34.48USDUpdated Jul 19, 202652-Week Change
-30.34%vs all stocks
Beta
0.2020xvs all stocks
50-Day MA
18.58USDUpdated Jul 19, 2026200-Day MA
22.43USDUpdated Jul 19, 2026Avg 10-Day Volume
358.45KSharesUpdated Jul 19, 2026Avg 30-Day Volume
588.95KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.09USDUpdated Jul 19, 2026Other Income / Expense
-18.41MCHFFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -10396.2%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -103.962Industry median: -0.34Industry P5: -43.55Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.55
Altman Z-Score 6.13: safe zoneNotable
Altman Z-Score: 6.13
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1.39M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,389,038Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Biolight Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immix Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
SS Innovations International, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senores Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
KBC Corporation Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Dongguan Tarry Electronics Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Hichain Logistics Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown